Delivery Order SPE2DB22D3016-SPE2DB25FBJQ6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $10,662.57. This firm fixed-price delivery order, which is expected to be completed by October 3, 2025, represents a non-set-aside competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used...
- The Defense Logistics Agency awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) on September 12, 2025, with completion expected by October 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tagrisso is an oncology medication used in the treatment of non-small cell lung cancer,...
- The Defense Logistics Agency awarded a $58,164.68 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of September 24, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this order supports the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $42,650.28 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy medication, and this delivery order represents one...
- The Defense Logistics Agency awarded a delivery order valued at $10,641.07 to AmerisourceBergen Drug Corp for the supply of Tagrisso 40 mg tablets (30-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a targeted cancer therapy used in treating certain lung cancers,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tagrisso 80 mg tablets in a quantity of 30 units, with a contract ceiling value of $10,662.57. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is scheduled for completion by September 30, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $10,662.57 to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count packages). This competitive award, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance of this contract will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Tagrisso 80 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $10,662.57. The order is scheduled for completion by September 2, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tagrisso 80 mg tablets (30-count units) with a ceiling value of $53,312.85 under a firm fixed-price contract type. This award, issued on September 10, 2025, with an ultimate completion date of October 1, 2025, represents a competitively awarded, non-set-aside order fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Tagrisso 80 mg tablets (30-count units) with a contract ceiling value of $63,975.42. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively obtained. The order is scheduled for ultimate completion by August 4, 2025, with fulfillment taking place at AmerisourceBergen's corporate office location...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBJQ6Delivery Order
The Defense Logistics Agency awarded a $42,650.28 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Tagrisso 80 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 7, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tagrisso is a prescription oncology medication used in the treatment of certain lung cancers, and this award represents a routine pharmaceutical procurement through the federal medical supply chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling and runs through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of medications and medical supplies to support military healthcare programs and the Defense Health Agency. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, holds a significant position as a critical federal vendor for medical procurement, with a history of competitively awarded contracts demonstrating its capability to meet federal pharmaceutical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $42.7k | 9/16/25 |